Literature DB >> 30219911

FA01.03: USE OF 'NON-TUBE NO FASTING' ERAS PROTOCOL IN PATIENTS AFTER MIE WITH LI'S ANASTOMOSIS: OUTCOMES IN THE FIRST 113 PATIENTS PERFORMED BY A SURGEON AFTER TRAINING COURSE.

Ruixiang Zhang1, Yin Li2, Shilei Liu1, Xianben Liu1, Haibo Sun1, Zongfei Wang1, Yan Zheng1, Xiankai Chen1, Qi Liu1, Zhengshuai Zhu1, Lei Xu1.   

Abstract

BACKGROUND: Use of enhanced recovery after surgery(ERAS) protocol in the patients after esophagectomy is reported to be feasible and safe in recent studies. And in Prof. Yin Li's research, patients after minimally invasive esophagectomy(MIE) with Li's anastomosis took oral feeding on the 1st day after operation (POD1). However, all the esophagectomy-procedures were proceeded by experienced experts. There was no report regarding whether ERAS protocol after MIE with Li's anastomosis could be safely proceeded by a young surgeon after training course. The aim of this study was to evaluate the feasibility and safety of 'Non-Tube No Fasting' ERAS Protocol in patients after MIE with Li's Anastomosis proceeded by a surgeon after the training course.
METHODS: We retrospectively reviewed the clinical data of patients who underwent MIE for cancer from December 2015 to September 2017 by a new surgical team finished MIE training course in our department. During the study period, the new team performed Mckeown MIE with Li's anastomosis for 127 esophageal cancer patients. We analyzed the data of 113 patients who followed the protocol of 'Non-tube No Fasting' ERAS. The primary end-points were the incidence of anastomotic fistula, the injury of recurrent laryngeal nerve, pneumonia, and postoperative length of hospital-stay.
RESULTS: All the 113 patients began oral feeding on POD1. Two patients exited the ERAS protocol on account of bucking caused by recurrent laryngeal nerve injury on POD3. The incidence of anastomotic fistula, recurrent laryngeal nerve injury and pneumonia were 3.5% (4/113), 12.4%(14/113) and 18.5%(21/113). The average length of postoperative hospital-stay was 8.6 ± 6.9 days. Both of the in-hospital mortality and 30-day mortality were 0.
CONCLUSION: Our date indicated that it was feasible and safe for a selected surgeon after 'Non-tube no fasting' ERAS and MIE training courses to proceed the protocol. Of course, more clinical researches are needed to confirm this result. DISCLOSURE: All authors have declared no conflicts of interest.

Entities:  

Mesh:

Year:  2018        PMID: 30219911     DOI: 10.1093/dote/doy089.FA01.03

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.

Authors:  Tao Song; Qi Yao; Jinrong Qu; Hongkai Zhang; Yan Zhao; Jianjun Qin; Wen Feng; Shouning Zhang; Xianhua Han; Shaoyu Wang; Xu Yan; Hailiang Li
Journal:  Eur Radiol       Date:  2020-09-08       Impact factor: 5.315

2.  Novel Criterion Using Esophageal Major and Minor Axes is Useful to Evaluate the Therapeutic Effect and Prognosis After Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Esophageal Cancer.

Authors:  Naoya Yoshida; Yusuke Taniyama; Kentaro Murakami; Tomo Horinouchi; Kozue Takahashi; Shinya Shiraishi; Kojiro Eto; Takashi Kamei; Hisahiro Matsubara; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2021-07-14       Impact factor: 5.344

3.  Outcome of chemoradiotherapy using intensity-modulated radiation therapy for cervical esophageal cancer: a single institute experience.

Authors:  Masahiro Inada; Yasumasa Nishimura; Kazuki Ishikawa; Takuya Uehara; Yutaro Wada; Yasuo Oguma; Hiroshi Doi; Kiyoshi Nakamatsu
Journal:  Esophagus       Date:  2021-01-08       Impact factor: 4.230

4.  Effectiveness of the Tailored, Early Comprehensive Rehabilitation Program (t-ECRP) based on ERAS in improving the physical function recovery for patients following minimally invasive esophagectomy: a prospective randomized controlled trial.

Authors:  Funa Yang; Lijuan Li; Yanzhi Mi; Limin Zou; Xiaofei Chu; Aiying Sun; Haibo Sun; Xianben Liu; Xiaoxia Xu
Journal:  Support Care Cancer       Date:  2022-02-22       Impact factor: 3.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.